Adjuvant use of combination of antibiotics in acute severe ulcerative colitis: A placebo controlled randomized trial
Autor: | Jimil Shah, Dimple Kalsi, Harjeet Singh, Usha Dutta, Arup Choudhury, Sant Ram, Harshal S Mandavdhare, Shubhra Mishra, Jayanta Samanta, Arun Sharma, Vishal Sharma, Kaushal K Prasad |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
Male 0301 basic medicine Microbiology (medical) medicine.medical_specialty medicine.medical_treatment 030106 microbiology Azathioprine macromolecular substances Placebo Severity of Illness Index Microbiology Gastroenterology Inflammatory bowel disease law.invention Young Adult 03 medical and health sciences 0302 clinical medicine Double-Blind Method Randomized controlled trial law Metronidazole Virology Internal medicine medicine Adjuvant therapy Humans 030212 general & internal medicine Infusions Intravenous business.industry Ceftriaxone Length of Stay Middle Aged medicine.disease Ulcerative colitis Infliximab Anti-Bacterial Agents Treatment Outcome Infectious Diseases Acute Disease Colitis Ulcerative Female business Adjuvant Follow-Up Studies medicine.drug |
Zdroj: | Expert Review of Anti-infective Therapy. 19:949-955 |
ISSN: | 1744-8336 1478-7210 |
Popis: | Evaluation of a combination of antibiotics as an adjuvant therapy in acute severe ulcerative colitis (ASUC). Patients with ASUC were randomized to either infusions of placebo or intravenous ceftriaxone and metronidazole in addition to standard care. Primary outcome was response on day three according to Oxford���s criteria. Secondary outcome measures included changes in partial Mayo score, CRP levels, fecal calprotectin (day three), and need for second-line therapy, hospital stay, and mortality (day 28). Fifty patients (25 in each group, median age: 33 years, 23 males) were included. The number of patients with fulminant disease in the antibiotic group were 16 (64%) as compared to 7 (28%) in the standard of care group. Complete response on day three was attained by 7 (28%) in the antibiotic and 6 (24%) standard of care group (p = 1.00). Three patients from the antibiotic group underwent colectomy and three received intravenous cyclosporine whereas four patients in the standard of care group received cyclosporine (p = 0.725). There was no significant difference in change in CRP, Partial Mayo score, and fecal calprotectin between the two groups on day three. Combination of intravenous ceftriaxone and metronidazole did not improve outcomes in ASUC. Acronym: AAASUC trial Registration Number: CTRI/2019/03/018196 and NCT03794765 |
Databáze: | OpenAIRE |
Externí odkaz: |